Compare FRST & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | BCYC |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.0M | 310.7M |
| IPO Year | 2006 | 2019 |
| Metric | FRST | BCYC |
|---|---|---|
| Price | $15.23 | $4.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 183.5K | ★ 292.3K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $50.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $3.99 |
| 52 Week High | $15.48 | $9.18 |
| Indicator | FRST | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 65.94 | 32.14 |
| Support Level | $13.71 | N/A |
| Resistance Level | N/A | $4.75 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 86.00 | 5.96 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.